VA-DXC-TECHNOLOGY
DXC Technology (NYSE: DXC) today introduced an advanced Patient-Centered Care solution, a customizable and personalized-health offering that gives healthcare providers the technology to meet the high expectations of today’s patients — without sacrificing cost containment and clinician satisfaction.
The healthcare industry is experiencing a value-based shift of epic proportions, driven by key external trends like an aging population; the proliferation of chronic diseases; rising healthcare costs; staffing shortages; and digital citizenship creating more informed patients. To elevate the patient experience, improve individual outcomes and create a healthier population, healthcare leaders are seeking new business and integrated care models that merge healthcare and life sciences while empowering patients and providers alike.
To help solve these challenges, DXC Patient-Centered Care provides advanced patient-engagement tools that offer convenient care from anywhere, via phone or tablet, at an affordable price. Backed by DXC’s interoperability, analytics and security products, the solution enables providers to access a continuous stream of patient-care data, helping them put the patient first throughout the continuum of care.
“In the age of ‘Dr. Google’ and same-day Amazon deliveries, patients are increasingly more demanding. They will no longer tolerate half-day waits for discharge instructions that could be delivered in seconds via a chatbot, or receive test results by snail mail when they could be viewed immediately on a mobile app. They expect better value and engagement from caregivers, driving the industry to move from traditional care-delivery models toward a patient-centered journey of care,” said Andrea Fiumicelli, vice president and general manager, Healthcare and Life Sciences , DXC Technology. “Our new Patient-Centered Care solution combines DXC’s industry expertise and leading healthcare technology to equip providers with custom-built, next-generation and coordinated care solutions.”
“The future of connected healthcare is centered around collaboration and care, and today’s busy providers need to find innovative ways to connect with their patients within and beyond the walls of a hospital or clinic,” said Dr. Michael Dahlweid, who recently joined DXC as its new global chief medical officer. “Our goal is to enable care teams to share health information across multiple systems, channels, practices and infrastructures, and aggregate it into a secure, consolidated view of the patient’s history of care. This persona-based access to real-time health data will allow clinicians to make the best possible decisions for their patients’ treatment. With speed, scale, flexibility and continuous innovation, DXC Technology prepares traditional healthcare organizations to become major digital-health enablers.”
The DXC Healthcare Portfolio
Patient-Centered Care is the newest solution in DXC’s extensive healthcare portfolio that is transforming the healthcare industry. The portfolio also includes:
- DXC Open Health Connect , a healthcare platform that helps improve healthcare outcomes by creating a connected ecosystem for patients, providers and payers.
- DXC Healthcare Cloud , a cloud-based solution that reduces complexity and risk while allowing approved parties to securely access applications and data 24/7.
- DXC Healthcare Security Services — for which DXC was recently named a leader in the Everest Group PEAK Matrix Assessment 2020 — to help healthcare providers quickly identify and respond to threats, protect data and patient privacy, and securely manage patient identities stored on-premise or in the cloud.
- DXC Health360 ™ , a cloud-based solution that enables providers and payers to personalize care experiences, deliver quality and increase customer loyalty at a lower cost.
- DXC Life Sciences solutions , which give life sciences organizations — including all 12 U.S. Fortune 500 pharmaceutical companies — the tools they need to accelerate innovation, improve operational efficiencies and reduce time to market for new therapies, devices and medicines.
About DXC Technology
DXC Technology (NYSE: DXC) helps global companies run their mission critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security and scalability across public, private and hybrid clouds. With decades of driving innovation, the world’s largest companies trust DXC to deploy our enterprise technology stack to deliver new levels of performance, competitiveness and customer experiences. Learn more about the DXC story and our focus on people, customers and operational execution at www.dxc.technology .
# # #
View source version on businesswire.com: https://www.businesswire.com/news/home/20200318005372/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 09:05:00 CET | Press release
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver
RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 09:00:00 CET | Press release
RoslinCT is performing technology transfer and will support commercial manufacture of Omisirge® for an additional indication following successful clinical trialsOmisirge® now FDA-approved for an expanded patient population in hematologyRoslinCT continues to support and advance multiple cell therapy projects at its Hopkinton, MA facility Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support c
Echoworx Secures FSQS-Netherlands Certification, Strengthening Trust in Financial Data Protection16.12.2025 07:00:00 CET | Press release
Leading encryption provider deepens commitment to European financial sector with rigorous new supplier qualification, building on existing UK & Ireland certification. Echoworx, a global leader in email and data encryption, proudly announces it has achieved Financial Services Qualification System (FSQS) registered supplier status for the Netherlands. This certification powerfully demonstrates Echoworx’s commitment to the highest standards of security and compliance. This achievement expands on the company’s existing FSQS certification for the UK and Ireland, secured in 2020. By successfully completing the rigorous qualification for the Netherlands, Echoworx reinforces its alignment with the stringent demands of the European financial market. The FSQS system, managed by Hellios, provides a single, reliable standard for vetting third-party suppliers, streamlining procurement for major banks and financial institutions. Think of FSQS as a high-security passport for technology partners. It p
Nippon Electric Glass to Start World’s First Mass Production of Low-Carbon Pharmaceutical Glass Tubing Using an All-Electric Furnace16.12.2025 03:00:00 CET | Press release
Nippon Electric Glass Co., Ltd. (NEG)(TOKYO:5214), a global leader in specialty glass headquartered in Otsu, Japan, announced it will begin the world’s first mass production of pharmaceutical-grade glass tubing using an all-electric melting furnace. Commercial production is scheduled to start in December 2025 at its subsidiary in Selangor, Malaysia. This breakthrough introduces a new manufacturing model for pharmaceutical packaging. By combining NEG’s proprietary all-electric melting technology with renewable energy, CO2 emissions from glass tubing production can be reduced by up to 90%*1 compared with conventional fossil-fuel combustion furnaces. This positions NEG as a major supplier capable of delivering both high-performance borosilicate glass and a significantly lower carbon footprint, directly addressing global sustainability demands from pharmaceutical companies and regulators. NEG is a leading global supplier of arsenic-free, environmentally friendly borosilicate glass tubing f
Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform16.12.2025 02:00:00 CET | Press release
Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster’s cell line platform. The technical reports of process, analytical, and formulation development, exosome drug loading, GMP engineering runs, and stability studies supported Shine-On’s IND submission. The IND was cleared by the U.S. FDA in Q1 2025. Furthermore, Esco Aster is providing technical services for exploratory exosome loading feasibility studies per Shine-On’s instruction. Shine-On Biomedical is an emerging innovator in exosome-based drug delivery. ShineOn’s proprietary product, SOB100, a HLA-G targeted exosome drug delivery carrier, has passed the U.S. FDA IND review and ongoing Phase I study, making it as a first-in-class–potential HLA-G targeted exosome platfo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom